Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination
Related publications (65)
Graph Chatbot
Chat with Graph Search
Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Ruthenium-based compounds are an attractive alternative to clinically used platinum drugs due to several features including a wide range of accessible oxidation states, varied synthetic chemistry and typically lower general toxicities. One series of ruthen ...
Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of these systems may explain the observed influence of the donor atoms on t ...
NOVELTY - A formulation comprising one or more components chosen from interleukin (IL)-2 or a derivative thereof coupled to a transport protein, a monoclonal anti-IL-2 antibody, a cancer vaccine based on specific antigens of tumors or tumor growth factors ...
Ten complexes of general formula [Ru(η6-arene)Cl2(L)], [Ru(η6-arene)Cl(L)2][X], and [Ru(η6-arene)(L)3][X]2 (η6-arene = benzene, p-cymene; L = imidazole, ...
An investigation of the mol. mechanism of the anticancer activity demonstrated by the ruthenium(II)-arene compd. [Ru(η6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed "RAPTA-C", in Ehrlich ascites carcinoma (EAC) bearing mice is descr ...